Showing results (151-160 of 905) with videos related to
Sort By:
Pageof 91
BMC Medicine|June 6, 2013
The collateral circulation of the heartPascal Meier, Stephan H Schirmer, Alexandra J Lansky, et al.European Journal of Heart Failure|January 28, 2014
Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failureJavaid Iqbal, Yasir Parviz, Bertram Pitt, et al.JACC. Heart Failure|May 15, 2017
Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the PROFILE Trial After 24 YearsMilton Packer, Bertram Pitt, Jean-Lucien Rouleau, et al.European Heart Journal|May 28, 2026
Optimal serum potassium concentrations in heart failure: an individual patient data meta-analysisRyohei Ono, Misato Chimura, Kieran F Docherty, et al.Journal of the American College of Cardiology|March 5, 2021
Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal FunctionIris E Beldhuis, Peder L Myhre, Michael Bristow, et al.Journal of the American College of Cardiology|January 2, 2025
Systolic Blood Pressure and Pulse Pressure in Heart Failure: Pooled Participant-Level Analysis of 4 TrialsHenri Lu, Toru Kondo, Brian L Claggett, et al.Circulation. Heart Failure|October 22, 2021
Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection FractionMasatoshi Minamisawa, Brian Claggett, Kota Suzuki, et al.Journal of Cardiac Failure|April 8, 2026
Performance of the HFpEF-ABA, H2FPEF, and HFA-PEFF Algorithms in HFpEF: A Participant-Level Pooled Analysis of Randomized Clinical TrialsJohn W Ostrominski, Fernando A Lara Lince, Brian L Claggett, et al.The Lancet. Diabetes & Endocrinology|April 16, 2014
Heart failure: a cardiovascular outcome in diabetes that can no longer be ignoredJohn J V McMurray, Hertzel C Gerstein, Rury R Holman, et al.Clinical Research in Cardiology : Official Journal of the German Cardiac Society|June 29, 2019
Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trialsSusan Stienen, Patrick Rossignol, António Barros, et al.Pageof 91